For nearly 40 years, cancer researchers struggled with a known problem. A mutation in a gene called KRAS drives some of the deadliest tumors, including pancreatic, lung, and colorectal cancers. Every attempt to create a drug that could block it failed. The KRAS protein had no clear spot for a drug molecule to attach to, so nothing could stop it. Scientists called it “undruggable,” not as a final judgment, but as a honest statement of how hard the problem was.
Now, a drug called daraxonrasib may have made progress against this mutation. When results from a phase 3 clinical trial were presented at the 2026 American Society of Clinical Oncology annual meeting in late May, the audience stood to applaud. The drug marks a real step forward in pancreatic cancer treatment and brings hope that doctors and patients have not had in years.
About the study
The phase 3 trial enrolled 500 patients with metastatic pancreatic cancer whose disease had stopped responding to first-line chemotherapy. This is one of the hardest patient groups to treat. Standard second-line options have historically offered a median survival of just 4.8 to 5.9 months, with no clear best approach. Patients were randomly assigned to receive either daraxonrasib, an oral pill taken once daily, or standard chemotherapy chosen by their doctor.
Daraxonrasib works differently from earlier attempts to target KRAS. Instead of trying to block the protein directly, which failed for decades because the surface was too smooth, it uses a “molecular glue” mechanism. The drug essentially glues a helper protein onto the mutant KRAS, locking it in an “off” position so it can no longer send the growth signals that fuel the cancer. This approach avoids the slippery-surface problem entirely and works across multiple types of KRAS mutations, not just one.
Daraxonrasib nearly doubled survival time
Patients on daraxonrasib lived an average of 13.2 months, compared to 6.7 months for those on standard chemotherapy. This represents a 60% reduction in the risk of death. That kind of improvement is rarely seen in clinical trials for this disease.
Tumors shrank in 33% of daraxonrasib patients, versus 12% on chemotherapy. Tolerability of the medications was also better: only 1.2% of patients on daraxonrasib stopped treatment due to side effects, compared to 11.2% on chemotherapy. That is a meaningful difference for people already managing a serious illness.
Earlier-stage testing of daraxonrasib showed similar results. Tumors shrank in 35% of a smaller group of patients, with a median survival of 13.1 months. The larger phase 3 trial confirmed those findings held up.
Why this goes beyond pancreatic cancer
Pancreatic cancer is where this story starts, but it is far from where it ends. KRAS mutations are among the most common cancer-driving mutations in humans. The mutation that daraxonrasib targets accounts for roughly 40% of pancreatic cancers, approximately 25% of lung cancers, and 40% of colorectal cancers.
The inability to target KRAS for decades meant that patients with these mutations had no drug designed specifically for their tumor’s genetic driver. The molecular glue approach that finally worked in pancreatic cancer is the same mechanism researchers are now testing in lung, colorectal, and other KRAS-driven cancers. It is a pattern that echoes what happened with BRCA mutations, where a discovery in one cancer type turned out to have implications across many others.
What this means for patients
Daraxonrasib is not yet commercially available, but phase 3 data like this is typically what leads researchers to submit a drug for FDA approval. While waiting for this drug to become more widely accessible, patients should ask about genetic testing for their tumor. Because daraxonrasib targets KRAS mutations, it is important to know whether a tumor carries this specific mutation. Most pancreatic cancers do, but a simple molecular test can confirm it.
Patients should also ask about clinical trials. Even before approval, expanded access programs or ongoing trials may be an option. An oncologist who specializes in pancreatic cancer or GI cancers is the best person to ask. Watching the approval timeline is also important. Phase 3 data presented at major oncology conferences like ASCO often precedes an FDA submission within months.
For patients with KRAS-mutated lung or colorectal cancer, the implications are more forward-looking. Daraxonrasib is being studied in those tumor types as well, and the mechanism that worked in pancreatic cancer is the same one being tested there. Understanding genetic risk and asking care teams about mutation testing is a reasonable first step.
The takeaway
For 40 years, KRAS was the mutation researchers knew was driving some of the deadliest cancers, but they could not do anything about it. This molecular glue mechanism finally cracked a problem that frustrated oncologists for decades. The phase 3 results speak for themselves: nearly double the survival time, a fraction of the side effects, and a mechanism that applies across multiple cancer types.
While this story starts with pancreatic cancer, the implications are much wider. KRAS mutations drive roughly a quarter of lung cancers and 40% of colorectal cancers, so this drug could have major impacts on these cancers too. This is the kind of trial result that moves science forward.
